Diagnose and manage Bartholin gland disease and benign vulvar and vaginal masses

In one line

Most Bartholin and benign vulvovaginal swellings are simple obstructive cysts or polymicrobial abscesses managed by drainage that creates a permanent epithelialised tract — but the single decision that defines specialist practice is recognising the minority that is not benign: a new Bartholin-area mass in a woman over 40 is carcinoma until a biopsy says otherwise, and an infiltrative solid vulvar mass demands tissue before it demands surgery.

Mechanism & pathophysiology

The two Bartholin (greater vestibular) glands sit at the 4 and 8 o'clock positions of the vestibule, each a pea-sized racemose gland whose 2.0–2.5 cm duct opens into the groove between the hymenal ring and the labium minus. They are the lubricating glands of the introitus, secreting mucus under sexual arousal; in health they are neither palpable nor visible, and the duct — not the gland — is the part that fails. When the distal duct is occluded (by inspissated mucus, post-inflammatory scarring, or trauma including episiotomy and the shearing of childbirth), secretion continues behind the block and the duct distends into a retention cyst, typically 2–4 cm, lined by the duct's transitional/squamous epithelium and filled with sterile mucus.

The cyst becomes an abscess when that stagnant cavity is colonised — and the bacteriology is the clinically useful part. These are polymicrobial, opportunistic infections dominated by the woman's own vaginal and enteric flora: coliforms (Escherichia coli the single commonest isolate), Staphylococcus and Streptococcus species, and anaerobes such as Bacteroides. In a representative 78-case series only three-quarters were culture-positive and neither Neisseria gonorrhoeae nor Chlamydia trachomatis was isolated at all — so while gonococcal and chlamydial involvement is described (older series quote N. gonorrhoeae in roughly 1–17%), the modern abscess is far more often a banal mixed-flora infection than a sexually transmitted one. Two corollaries follow directly. First, empirical cover must target gut and skin flora, not just gonococcus, and the community spread of methicillin-resistant S. aureus means staphylococcal cover can no longer be assumed adequate against MRSA where it is prevalent. Second, the abscess is roughly three times commoner than the bland cyst, because a warm obstructed mucus-filled cavity at the introitus is an ideal culture medium — which is why most clinical presentations are acute and painful rather than incidental.

Benign cysts and masses elsewhere on the vulva and in the vagina are best understood embryologically, because the developmental origin predicts both the site and the behaviour:

• Gartner duct cysts are remnants of the mesonephric (Wolffian) duct, which in the female should regress. Persisting fragments lie along the anterolateral vaginal wall and are the commonest benign vaginal cyst; Wolffian remnants are found in about a quarter of adult women but only around 1% form a clinically apparent cyst. Their lateral position and their association — uncommonly — with mesonephric/renal tract anomalies distinguish them from a midline anterior cyst.
• Hydrocele of the canal of Nuck is the female counterpart of a patent processus vaginalis: the canal of Nuck accompanies the round ligament through the inguinal canal towards the labium majus, and failure of obliteration leaves a peritoneal-lined sac that fills with fluid, presenting as a non-reducible inguino-labial swelling that does not change with Valsalva. It is the gynaecological mimic of an inguinal hernia and is the reason an upper-outer labial cystic swelling is not a Bartholin problem at all.
• Epidermal (epidermoid) inclusion cysts arise from keratinising squamous epithelium buried by trauma, episiotomy or female genital cutting; they are the commonest solid-feeling vulvar cyst, contain caseous keratin, and sit superficially in the labia.
• Mucous (mucinous) vestibular cysts derive from minor vestibular glands of urogenital-sinus origin and cluster around the urethral meatus and vestibule.
• Skene (paraurethral) duct cysts arise from the female homologue of the prostate, lie alongside the distal urethra, and matter because they can distort the meatus and be mistaken for a urethral diverticulum.

The benign solid masses are mesenchymal and span a behavioural spectrum that the histology, not the clinical feel, defines. Lipomas and fibromas are indolent. Vulvar leiomyomas arise from smooth muscle of the round ligament or erectile tissue. The two that matter are paired and constantly confused: angiomyofibroblastoma is a small, well-circumscribed, genuinely benign myofibroblastic tumour that is cured by local excision and essentially never recurs; aggressive (deep) angiomyxoma is its dangerous mimic — a large, poorly circumscribed, infiltrative mesenchymal tumour (WHO "tumours of uncertain differentiation") that entraps fat, muscle and nerve, is strongly oestrogen- and progesterone-receptor positive, and recurs locally in 36–72% of cases, sometimes years after apparently complete excision. The whole point of naming them together is that they can look and feel identical at the bedside and only the pathologist's reading of the margin and the growth pattern tells you whether you have performed a cure or merely started a long surveillance.

Why the over-40 rule exists — the carcinoma that hides in a cyst

The mechanistic justification for biopsying older women is that the Bartholin gland is a branching duct-and-acinar structure lined by three epithelia — mucinous acini, transitional duct, and squamous distal duct — and a carcinoma can arise from each, giving Bartholin gland carcinoma its histological variety: adenocarcinoma from the acini, squamous carcinoma from the distal duct, and the slow, perineurally invasive adenoid cystic carcinoma that is characteristic of this site. Two features make it treacherous. First, because the tumour begins deep in the gland it presents as a smooth, intact, cyst-like swelling long before it ulcerates — it feels exactly like the benign retention cyst it is mistaken for, which is why repeated "drainage" can continue for months. Second, its peak incidence is in the sixth and seventh decades, precisely the age at which a genuinely new Bartholin cyst is uncommon, because the gland normally involutes after the menopause and rarely obstructs de novo. A new Bartholin-area swelling appearing for the first time in a postmenopausal woman is therefore not just statistically more likely to be malignant; it is biologically anomalous, and that anomaly is the signal. The corollary the specialist must hold is that the diagnosis of "Bartholin cyst" is itself age-dependent — common and benign in the twenties, increasingly a diagnosis of exclusion after 40.

Assessment

The assessment task is triage into one of three buckets — cyst, abscess, or neoplasm — because each carries a different urgency and a different next step, and the commonest error is to treat every introital swelling as a Bartholin abscess.

• History. A tense, rapidly enlarging, exquisitely painful unilateral introital swelling over a few days, often with difficulty sitting or walking and sometimes with spontaneous purulent discharge as it points, is an abscess. A soft, slowly growing, painless or mildly uncomfortable swelling in the same posterolateral location is a cyst. A mass that is solid, fixed, ulcerated, indurated, persistently growing, or recurs after what should have been definitive drainage is the one that earns a biopsy.
• Examination. Inspect and palpate the vestibule directly. A Bartholin lesion is posterolateral, at 4 or 8 o'clock, and unilateral. Document the location precisely, because an anterolateral vaginal-wall cyst is a Gartner duct cyst, a periurethral cyst is Skene or a urethral diverticulum, and an upper-outer labial/inguinal swelling is a canal-of-Nuck hydrocele or hernia — none of which are drained like a Bartholin abscess. Feel for fluctuance (collection), induration and fixity (think neoplasm), and surrounding cellulitis (which changes antibiotic decisions). Examine the inguinal nodes.
• Age is itself an investigation. In a woman over 40, and certainly postmenopausally, a new Bartholin-region mass cannot be assumed benign: Bartholin gland carcinoma (adenoid cystic, adenocarcinoma, squamous) accounts for under 2% of vulvar cancers but is classically a disease of the post-menopause that masquerades as a cyst or abscess until it is too late. The defensible rule is that her age lowers the biopsy threshold to near zero — drainage of a "cyst" in this group should be accompanied by histology of the wall, and a solid or recurrent lesion mandates a formal biopsy before any definitive operation.
• Investigations are selective, not reflexive. Most young women with a typical abscess need no imaging and no swabs beyond clinical judgement — antibiotics are not even routinely indicated (see Management). Send a charcoal swab for culture and sensitivity when there is cellulitis, systemic features, recurrence, immunosuppression or treatment failure; add gonorrhoea and chlamydia testing (NAAT) when there is an STI risk profile, recognising that the yield is low. In South Africa an HIV test belongs in the work-up of recurrent or atypical abscesses, because immunosuppression both predisposes to recurrent vulvar sepsis and widens the differential (including unusual organisms and the more aggressive behaviour of any underlying malignancy). Imaging is for the atypical mass: ultrasound differentiates a canal-of-Nuck hydrocele from a hernia and characterises a deep cystic lesion, while MRI is the investigation for a solid infiltrative vulvar mass — an aggressive angiomyxoma shows its characteristic "swirled"/layered high-T2 signal and, crucially, reveals the true deep extent that the examining finger underestimates, which is what makes the difference between a planned wide excision and an inadequate "shelling out".

The differential by location — a map for the examining finger

The reason location dominates the assessment is that each benign swelling betrays its embryological origin by where it sits, and the management diverges sharply, so the single most useful discipline is to fix the lesion's position before reaching for a scalpel:

The map also disciplines the history: a swelling that fluctuates with the menstrual cycle, that has been present unchanged since adolescence, or that enlarges with Valsalva each point away from a Bartholin abscess and towards a specific alternative the finger should already have located.

Management

Organise around the clinical category, and within the abscess pathway think immediate → ongoing → long-term, because the recurrence problem is what separates a competent drainage from a definitive one.

The asymptomatic cyst in a young woman needs no treatment — reassurance and safety-netting. Intervene only for symptoms, size, recurrent infection, or the diagnostic indications above (age >40, solid/atypical features).

The Bartholin abscess (or symptomatic cyst):

• Do not simply incise and drain. Plain incision and drainage, and needle aspiration alone, give the highest recurrence because they do not create a permanent drainage tract — the duct re-occludes and the cycle repeats. The principle of definitive treatment is to fistulise the gland: create a new epithelialised opening that keeps draining permanently. The two standard ways to achieve this are the Word catheter and marsupialisation, and they are essentially equivalent on the only outcome that matters.
• Word catheter is the office/emergency-department procedure of choice: under 1% lignocaine, a small (≈5 mm) stab incision is made into the cyst on the mucosal surface just exterior to the hymenal ring (never on the labial skin, or the fistula scars outward), the balloon-tipped catheter is passed into the cavity and inflated with up to ~3 mL of saline, and it is left in situ for about four weeks to let an epithelialised fistula form before it is deflated and removed. It is quick, needs only local anaesthetic, and is markedly cheaper than theatre.
• Marsupialisation everts the cyst wall and sutures it to the surrounding skin edge, creating the same permanent ostium; it is a theatre procedure under general or regional anaesthesia, reserved for recurrent disease, very large cysts, patient preference, or when a Word catheter has failed or cannot be retained. Routine packing is not required. A single intravenous antibiotic dose is reasonable at the time of surgery (co-amoxiclav 1.2 g, or clindamycin 900 mg if penicillin-allergic).
• Antibiotics are an adjunct, not the treatment. Drainage cures the abscess; antibiotics do not drain pus. In the absence of cellulitis, systemic features or risk factors, antibiotics are not indicated at all. When they are required — surrounding cellulitis, systemic sepsis, immunosuppression (including HIV), pregnancy, recurrence, or a high-risk STI profile — choose a broad-spectrum agent covering coliforms, anaerobes and skin flora (co-amoxiclav is the rational empirical default), narrowed on culture, and add MRSA-active cover (and consider gonococcal/chlamydial treatment) where the local epidemiology or risk profile demands it.
• Marsupialisation versus Word catheter — the evidence is reassuringly flat. They produce comparable recurrence (around 10–12% at one year), so the choice is driven by setting, anaesthetic access and cost rather than efficacy. In a South African district hospital the Word catheter's advantage is decisive: it is done under local anaesthetic in the casualty or outpatient department without a theatre slot, returns the woman to work the same day, and avoids the queue for a general anaesthetic that a marsupialisation requires — a resource argument that, for once, points the same way as the evidence.

Recurrent Bartholin disease is the indication to escalate. After repeated abscesses despite an adequate fistulising procedure, excision of the entire gland is the definitive — but not first-line — answer. It is reserved as a last resort because the gland sits in a vascular bed and excision risks significant haemorrhage, haematoma, dyspareunia and scarring; it is a theatre procedure, ideally in the quiescent phase rather than through acutely infected tissue. The same operation provides the histology that a recurrent mass in an older woman needs — so in the over-40 group, recurrence is doubly an argument for excision: it treats the disease and it excludes the carcinoma.

Getting the fistulising procedure right — the technical details that determine recurrence

The recurrence rate of a Word catheter or marsupialisation is not fixed at the 10–12% the trials report; it rises sharply when the technique is wrong, and the avoidable errors are specific. The incision must be on the mucosa just exterior to the hymenal ring, into the cyst cavity itself — an opening on the labial skin scars outward and a catheter that sits in the subcutaneous tissue rather than the cavity drains nothing. The stab incision should be small (around 5 mm): too large and the balloon will not be retained and falls out before an epithelialised tract has formed; too small and the cavity is incompletely decompressed. The catheter must stay in for the full four weeks — premature loss, whether because the woman removes it for discomfort or because it was placed through too generous an incision, is the commonest reason a "successful" drainage recurs, so counselling and follow-up to confirm retention are part of the procedure, not an afterthought. For marsupialisation, the everted edges must be sutured widely enough to leave a durable ostium; a tight closure stenoses and re-obstructs. When a Word catheter cannot be retained — a very large or multilocular cavity, or a labium that will not hold the balloon — that is itself the indication to convert to marsupialisation rather than to accept a failed drainage and a recurrence.

A practical caveat for the pregnant woman: a Bartholin abscess in pregnancy is drained as usual (the Word catheter is ideal and avoids anaesthesia), but the engorged, vascular peripartum gland makes excision hazardous, so definitive gland excision for recurrence is deferred until after delivery and the puerperal involution.

Benign cysts and masses elsewhere:

• Gartner duct, epidermal inclusion, mucous and Skene cysts that are asymptomatic need only reassurance; symptomatic or diagnostically uncertain lesions are excised, with the proviso that a periurethral cyst must be distinguished from a urethral diverticulum (which is managed quite differently) before any incision near the urethra.
• Canal-of-Nuck hydrocele is treated by surgical excision of the sac with closure of the patent canal, repairing the associated hernia where present — managed like the inguinal lesion it embryologically is, not like a vulvar cyst.
• Benign solid masses (lipoma, fibroma, leiomyoma, angiomyofibroblastoma) are cured by simple local excision, which is also diagnostic.
• Aggressive angiomyxoma is the exception that dictates planning. Because it infiltrates far beyond its apparent edge and recurs in well over a third of cases, it requires wide local excision with histologically clear margins, planned on MRI so the deep extent is known before the incision; "shelling out" a mass that turns out to be an angiomyxoma guarantees positive margins and recurrence. Given its strong ER/PR positivity, GnRH analogues have been used to shrink unresectable or recurrent tumours and to downsize before surgery, but the response is incomplete, regrowth follows withdrawal, and the long-term toxicity (menopausal symptoms, bone loss) limits it to an adjunct in selected cases rather than a substitute for excision. Because recurrence can appear years later, long-term clinical and imaging surveillance is part of the management, not an optional extra.

The practical consequence of getting the pathology wrong cuts both ways, and the consultant should be able to argue both directions. Over-treating a well-circumscribed angiomyofibroblastoma with mutilating wide excision is unnecessary morbidity for a tumour that simple excision cures; under-treating an angiomyxoma with conservative excision condemns a young woman to repeated recurrences and progressively larger operations. The only way to avoid both errors is to insist on the definitive histology before planning the definitive operation — an incisional or core biopsy of a solid infiltrative mass, read against MRI, rather than a therapeutic excision that commits to a margin chosen blind. This is the same discipline as the over-40 Bartholin rule, applied to the solid mass: tissue first, surgery second.

Guidelines compared

The bodies do not meaningfully disagree on the medicine: drainage that fistulises, antibiotics only when there is infection beyond the abscess itself, and a hard rule that age over 40 changes a "cyst" into a "rule out cancer". Where guidance is genuinely thin — and candidates should say so — is on whether any adjuvant antibiotic after adequate drainage changes recurrence, which remains unresolved.

The evidence & the controversy

The defining feature of this topic's evidence base is how little high-quality trial evidence underpins such common practice. The pre-2016 literature was almost entirely observational: a systematic review of 24 studies found only five randomised trials, the rest case series, and concluded it could not identify a best treatment — a candid admission that decades of confident drainage rested on tradition rather than data.

The WoMan trial (2017) is therefore the pivotal study, because it is the adequately powered randomised comparison the field had lacked. It allocated 161 women with a Bartholin cyst or abscess to a Word catheter or marsupialisation and found recurrence within one year was statistically indistinguishable — 12% versus 10% (RR 1.1, 95% CI 0.64–1.91) — while the Word catheter caused less early pain (33% versus 74% needed analgesia in the first 24 hours) and was far quicker to deliver (1 hour versus 4 from diagnosis to treatment). The honest reading is that the procedures are equivalent on the outcome that matters and the case for the office-based, local-anaesthetic Word catheter is one of pragmatism and cost rather than superior cure — which is exactly the argument that wins in a resource-limited service. A 2024 meta-analysis of 735 women confirmed this, finding no significant difference in recurrence (7.6% versus 9.4%; OR 0.99), so the equivalence is now as settled as the evidence in this area gets. Where some recent series have suggested marsupialisation edges ahead on recurrence and satisfaction, the randomised and pooled data do not support treating that as a reason to default to theatre.

The genuine controversies are at the margins. The first is antibiotic stewardship: the shift in bacteriology — away from a presumed gonococcal/chlamydial cause and towards mixed opportunistic flora with rising community MRSA — argues for less reflex antibiotic prescribing for the drained abscess and more targeted cover only when infection has spread, a stewardship message that sits awkwardly with the ingrained habit of "abscess equals antibiotics". The second, and the one with real medicolegal teeth, is the over-40 mass: every few years a case is reported of a Bartholin "cyst" repeatedly drained over months that proves to be carcinoma, and the lesson is that the convenience of office drainage must never override the discipline of biopsy in the older woman. The third is the quiet management problem of aggressive angiomyxoma, where the field still debates how wide an excision must be, whether mutilating radical surgery is justified for a histologically benign tumour, and what role hormonal therapy and even targeted agents play — an unresolved balance between local control and morbidity in a young woman who will live for decades with the possibility of recurrence.

A fourth, more contemporary, current runs underneath all three: the proliferation of silver nitrate ablation, alcohol sclerotherapy, CO₂-laser fenestration and a growing list of "minimally invasive" office techniques marketed as quicker or more definitive than the Word catheter. The honest appraisal is that almost all of this rests on small case series and a handful of underpowered trials; none has shown a recurrence advantage over the Word catheter that the WoMan trial and the 2024 meta-analysis would not regard as noise, and some (silver nitrate, alcohol) carry their own tissue-injury risks. The defensible specialist position is to treat the simple, cheap, evidence-backed fistulising procedures as the standard and to regard the newer ablative methods as unproven alternatives rather than improvements — a stance that also protects a resource-limited service from buying technology in search of a problem the Word catheter already solves.

Landmark trials & key evidence

Exam traps & red flags

• Treating every introital swelling as a Bartholin abscess. Location is diagnostic: posterolateral at 4/8 o'clock is Bartholin; an anterolateral vaginal-wall cyst is Gartner; a periurethral cyst is Skene or a urethral diverticulum; an upper-outer labial/inguinal swelling is a canal-of-Nuck hydrocele or hernia — and these are not drained the same way.
• Draining a "cyst" in a woman over 40 without histology. A new Bartholin-area mass in this group is carcinoma until biopsy proves otherwise; repeated drainage of an "abscess" that keeps recurring in an older woman is a classic missed Bartholin gland carcinoma.
• Plain incision and drainage or needle aspiration as definitive treatment. Both have the highest recurrence because they do not create a permanent epithelialised tract; the principle is to fistulise (Word catheter or marsupialisation), not just evacuate.
• Reflex antibiotics for every drained abscess. Drainage is the treatment; antibiotics are indicated only with cellulitis, systemic features, immunosuppression, pregnancy or recurrence — over-prescribing is poor stewardship, and where it is justified the cover must reach coliforms, anaerobes and (by risk) MRSA, not just gonococcus.
• Incising on the labial skin rather than the mucosal surface. A Word catheter or marsupialisation placed externally scars outward and fails; the opening must be made just exterior to the hymenal ring on the mucosa.
• "Shelling out" an infiltrative solid vulvar mass. An aggressive angiomyxoma needs MRI-planned wide local excision with clear margins; treating it as a simple cyst guarantees positive margins and recurrence (36–72%). Confusing it with the harmless, well-circumscribed angiomyofibroblastoma — which local excision cures — is the named pathology trap.
• Mistaking a periurethral cyst for a benign lesion and incising into a urethral diverticulum. Exclude a diverticulum before operating anywhere near the urethra.
• Forgetting HIV in the recurrent or atypical case. In the South African setting, recurrent vulvar sepsis or an unusual presentation warrants an HIV test, because immunosuppression changes both the microbiology and the index of suspicion for malignancy.

Evidence anchors

• WoMan trial — Kroese et al., BJOG 2017;124(2):243–249
• Word catheter vs marsupialisation — Bakouei et al., systematic review & meta-analysis, J Obstet Gynaecol Can 2024
• Management of Bartholin duct cysts and abscesses — Wechter et al., Obstet Gynecol Surv 2009;64(6):395–404 (systematic review)
• Microbiology of Bartholin cysts/abscesses and empirical antibiotics — Bhide et al., J Obstet Gynaecol 2010;30(7):701–703
• Management of Bartholin's cyst and abscess — NHS Scotland Right Decisions (Gynaecology 066)
• Bartholin gland cyst — anatomy, pathophysiology, malignancy threshold, treatment (StatPearls)
• Aggressive angiomyxoma of the vulva — review of management and recurrence (PMC10003322)
• Bartholin gland carcinoma — under 2% of vulvar malignancies, predominantly postmenopausal; the basis for the over-40 biopsy rule (StatPearls; NHS Scotland Right Decisions).
• Gartner duct cyst (mesonephric/Wolffian remnant) and hydrocele of the canal of Nuck (persistent processus vaginalis with the round ligament) — embryological origins of the principal non-Bartholin benign vulvovaginal cysts.